Climb Bio Inc
About
Climb Bio Inc (NASDAQ:CLYM) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 28 2026
Climb Bio, Inc. Announces $110.0 Million Private Placement
Apr 8 2026
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Apr 7 2026
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Mar 5 2026
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Mar 5 2026
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Financials
Revenue
$0
Market Cap
$459.56 M
EPS
-0.88